Dan Purser: Redefining Hyperhomocysteinemia Through 22 Critical SNPs
Dan Purser, Co-Founder of AO Biologix, LLC, shared a post on LinkedIn:
“Open Evidence AI finding—’The medical literature confirms that functional glutathione reduces cytokine formation at the monocyte level (Frontiers in Immunology, 2019)’
The ultimate guide to homocysteine: The Purser Model and The 60% Calamity
A Medical Manifesto for the 21st Century By Dan C. Purser
Introduction: The Semmelweis Moment
In 1847, Ignaz Semmelweis discovered that simple hand-washing could virtually eliminate childbed fever.
He was mocked, hounded, and eventually marginalized by an establishment that found his discovery too disruptive to the status quo.
Today, we face a similar ‘Semmelweis Moment.’
For nearly a century, medicine has viewed Hyperhomocysteinemia (HHcy) as a metabolic marker—a number to be ‘lowered’ with simple B-vitamins.
We were wrong.
After treating over 25,000 patients, I am declaring a national health calamity:
50–60% of the U.S. population is standing in the path of cytokine destruction that standard medicine simply cannot see.
Chapter 1: The Bull Elephant (Why 38.8% is a Lie)
Standard medical texts quote a comfortable statistic: 38.8% of the population has a homocysteine problem.
This figure is a relic of an era when we only looked at just a few genes: MTHFR C677T, A1298C, CBS and maybe MTRR, or MTR.
The Purser Model reveals a much darker reality.
By mapping the full genetic architecture, we have identified 22 specific homozygous SNPs—lifelong genetic ‘breaks’—that dictate a patient’s inflammatory setpoint.
When you account for this complete architecture, the number of affected individuals skyrockets to 60% of our civilization.
This is the bull elephant in the china shop, and it is leaving a trail of strokes, heart attacks, and kidney failure in its wake.”
Stay updated on all scientific advances with Hemostasis Today.
-
Aug 11, 2026, 04:10Haroun Gajraj: CLaCS vs Sclerotherapy – What Does the Evidence Show
-
Aug 11, 2026, 02:54Tareq Abadl: The Ultimate Guide to Clinically Significant Antibodies
-
Aug 10, 2026, 17:35Chokri Ben Lamine: Balancing Holistic Care and Precision in Hematology
-
Aug 10, 2026, 17:14Anna Stanizzi: Patient Blood Management as a New Model of Personalized Care
-
Aug 10, 2026, 17:12Odong Christopher: New Research on Ischemic Stroke Prediction in Uganda
-
Aug 10, 2026, 16:58Jeff Szer AM: Advancing the Management of Paroxysmal Nocturnal Hemoglobinuria
-
Aug 10, 2026, 16:51Suebsarn Ruksakulpiwat։ A New Milestone in the Development of the Stroke Risk Screening Scales
-
Aug 10, 2026, 16:09Preetie Shetty Akkunje: Making Stroke Rehabilitation Accessible in Low-Resource Settings
-
Aug 10, 2026, 15:50The Next Antithrombotic Frontier: GPVI Inhibitors Beyond Aspirin